Bayer settles some NSF cases
Radiology ‘Wikipedia’ settles in on web
Bayer settles some NSF cases
Bayer has tentatively settled between 30 and 40 lawsuits brought by patients who developed nephrogenic systemic fibrosis after the administration of Magnevist, its MR contrast agent. Only Bayer has so far reached any such settlements, according to Peter Burg, an attorney with Burg Simpson Eldredge Hersh & Jardine in Englewood, CO, who told DI SCAN that not all of the tentative deals involve his clients. Bayer and several other makers of gadolinium-based contrast agents are facing hundreds of lawsuits alleging a link between the administration of the agents and NSF, a potentially fatal disease characterized by uncontrolled growth of connective tissue in the skin and internal organs. In September 2007, the FDA asked manufacturers of these agents -- Bayer (Magnevist), GE Healthcare (Omniscan), Mallinckrodt/Tyco Healthcare (OptiMark), and Bracco Diagnostics (ProHance and MultiHance) -- to add a black-box warning about NSF. The agency at the time also warned patients with impaired kidney function to avoid gadolinium-containing agents.
Radiology ‘Wikipedia' settles in on web
A specialist version of Wikipedia aimed at the radiology community is on the web. Radiopaedia.org is a free online radiology resource built and maintained by users, who find and correct errors. Currently in beta form, Radiopaedia.org is being framed as the means to support discussion of difficult or controversial topics. Images and other materials can be submitted and downloaded for use by others under Creative Commons 3.0 license.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
